Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
Conditions
Interventions
Suzetrigine
Placebo (matched to SUZ)
Locations
65
United States
Central Research Associates, LLC
Birmingham, Alabama, United States
Accel Research - Birmingham
Birmingham, Alabama, United States
AMR Mobile
Mobile, Alabama, United States
Scottsdale Clinical Trials
Scottsdale, Arizona, United States
Hope Clinical Research
Canoga Park, California, United States
Marvel Clinical Research
Huntington Beach, California, United States
Start Date
November 21, 2025
Primary Completion Date
April 6, 2027
Completion Date
April 6, 2027
Last Updated
April 27, 2026
NCT06614322
NCT07285018
NCT06221241
NCT07377721
NCT05177094
NCT06122012
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions